NOVO NORDISK A/S

NYSE: NVO (Novo Nordisk A/S)

Last update: 25 Oct, 2:06AM

52.96

-0.27 (-0.51%)

  • 1D -0.51%
  • 5D 0.00%
  • 1M -11.22%
  • 6M -20.11%
  • YTD -39.49%
  • 1Y -49.73%
  • 5Y 50.54%
Previous Close 53.23
Open 53.41
Volume 8,321,969
Avg. Volume (3M) 18,254,114
Market Cap 236,407,062,528
Price / Earnings (TTM) 13.65
Price / Earnings (Forward) 14.08
Price / Sales 4.85
Price / Book 8.32
52 Weeks Range
45.05 (-14%) — 113.76 (114%)
Earnings Date 5 Nov 2025
TTM Dividend Yield 2.08%
Profit Margin 34.51%
Operating Margin (TTM) 49.68%
Diluted EPS (TTM) 3.67
Quarterly Revenue Growth (YOY) 19.50%
Quarterly Earnings Growth (YOY) 14.30%
Total Debt/Equity (MRQ) 85.70%
Current Ratio (MRQ) 0.740
Operating Cash Flow (TTM) 131.24 B
Levered Free Cash Flow (TTM) 77.73 B
Return on Assets (TTM) 23.29%
Return on Equity (TTM) 88.12%

Market Trend

Short Term Medium Term
Industry Drug Manufacturers - General (US) Bullish Bearish
Drug Manufacturers - General (Global) Bullish Bearish
Stock Novo Nordisk A/S Bullish Bearish

AIStockmoo Score

0.3
Analyst Consensus 1.5
Insider Activity NA
Price Volatility 4.5
Technical Moving Averages -2.5
Technical Oscillators -2.5
Average 0.25

Similar Stocks

Stock Market Cap DY P/E (TTM) P/B
NVO 236 B 2.08% 13.65 8.32
NVS 255 B 3.27% 19.16 6.04
LLY 787 B 0.32% 43.02 40.22
JNJ 450 B 1.33% 18.08 5.71
ABBV 387 B 1.50% 165.94 50.46
MRK 209 B 1.93% 11.09 4.28

With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Sector Healthcare
Industry Drug Manufacturers - General
Investment Style Large Core
% Held by Insiders 0.01%
% Held by Institutions 9.85%

Ownership

Name Date Shares Held
Everett Harris & Co /Ca/ 30 Jun 2025 6,394,182
52 Weeks Range
45.05 (-14%) — 113.76 (114%)
Price Target Range
47.00 (-11%) — 70.00 (32%)
High 70.00 (HSBC, 32.18%) Buy
70.00 (TD Cowen, 32.18%) Buy
Median 62.50 (18.01%)
Low 47.00 (Morgan Stanley, -11.25%) Sell
Average 60.50 (14.24%)
Total 2 Buy, 1 Hold, 1 Sell
Avg. Price @ Call 56.42
Firm Date Target Price Call Price @ Call
BMO Capital 14 Oct 2025 55.00 (3.85%) Hold 56.66
HSBC 02 Oct 2025 70.00 (32.18%) Buy 58.74
Morgan Stanley 29 Sep 2025 47.00 (-11.25%) Sell 55.50
TD Cowen 19 Aug 2025 70.00 (32.18%) Buy 54.78

No data within this time range.

  • 3M
Date Type Details
06 Nov 2025 CNBC Eli Lilly to start late-stage trials on amylin obesity drug after it shows up to 20% weight loss in study 
06 Nov 2025 CNBC Trump announces deals with Eli Lilly, Novo Nordisk to slash weight loss drug prices, offer some Medicare coverage
06 Nov 2025 CNBC Here's how much weight loss drugs could cost you under Trump's deals with Eli Lilly, Novo Nordisk
04 Nov 2025 CNBC Pfizer tops estimates, raises profit guidance even as sales fall
04 Nov 2025 CNBC Metsera says Novo Nordisk’s new up to $10 billion bid for obesity drugmaker is ‘superior’ to revised Pfizer offer
03 Nov 2025 CNBC Pfizer files second lawsuit against Novo Nordisk, Metsera in bidding war over obesity biotech
02 Nov 2025 CNBC Where the blockbuster weight loss drug market stands today — and what’s coming next
30 Oct 2025 CNBC Eli Lilly blows past estimates, hikes guidance as Zepbound and Mounjaro sales soar
30 Oct 2025 Announcement Metsera Receives Unsolicited Proposal from Novo Nordisk
30 Oct 2025 Announcement Novo Nordisk submits proposal to acquire Metsera, Inc.
29 Oct 2025 CNBC Eli Lilly, Walmart to offer first retail pickup option for discounted vials of weight loss drug Zepbound
21 Oct 2025 Announcement Novo Nordisk announces an Extraordinary General Meeting to be convened to elect new members of the Board of Directors
21 Oct 2025 Announcement Notice convening an Extraordinary General Meeting of Novo Nordisk A/S
17 Oct 2025 CNBC Eli Lilly and Novo Nordisk stocks fall as Trump says he wants $150 price for GLP-1s
15 Oct 2025 Announcement Novo Nordisk and Omeros announce asset purchase and license agreement for Omeros’ clinical-stage MASP-3 inhibitor zaltenibart (OMS906)
09 Oct 2025 Announcement Novo Nordisk to acquire Akero Therapeutics and its promising phase 3 FGF21 analogue to expand MASH portfolio
30 Sep 2025 Announcement SueWallSt Podcast Series Launches With Focus on Novo Nordisk A/S (NVO) Fraud Allegations
29 Sep 2025 Announcement Novo Nordisk A/S (NVO) Shareholders Get Answers in Latest SueWallSt Podcast
23 Sep 2025 CNBC Eli Lilly to build $6.5 billion Texas manufacturing facility for obesity pill, other drugs
22 Sep 2025 CNBC Pfizer boosts obesity drug prospects with $7.3 billion deal to buy Metsera
18 Sep 2025 Announcement Novo Nordisk A/S: Ozempic® reduces the risk of heart attack, stroke and death by 23% compared to dulaglutide in the first head-to-head real-world study
17 Sep 2025 CNBC Eli Lilly pill outperforms Novo Nordisk’s oral drug in head-to-head diabetes trial
17 Sep 2025 Announcement Novo Nordisk’s oral semaglutide 25 mg (Wegovy® in a pill*) delivered 16.6% weight loss in people with obesity in a newly published study
16 Sep 2025 CNBC Eli Lilly to build $5 billion Virginia facility to boost production of targeted cancer drugs, other treatments
16 Sep 2025 Announcement Novo Nordisk presents phase 3 data for next-generation amylin cagrilintide, leading to advancement into dedicated clinical programme
15 Sep 2025 Announcement People taking Novo Nordisk’s Wegovy® experienced reduced food noise and boosted mental well-being
15 Sep 2025 Announcement EU approval makes Novo Nordisk’s oral semaglutide the first and only oral GLP-1 RA to reduce cardiovascular death, heart attack and stroke
12 Sep 2025 CNBC Eli Lilly, Novo Nordisk prepare to face off in the next obesity drug battleground
11 Sep 2025 CNBC Health care inflation rises as patients, employers brace for biggest jump in health spending in 15 years
10 Sep 2025 Announcement Novo Nordisk to streamline operations and reinvest for growth
05 Sep 2025 Announcement Investors SueWallSt as Novo Nordisk A/S Faces Securities Fraud Allegations
05 Sep 2025 Announcement Novo Nordisk to present new semaglutide data on ‘food noise’, body composition and cardiovascular benefits, as well as pipeline data at the EASD diabetes congress
03 Sep 2025 Announcement Shareholders SueWallSt in New Class Action Against Novo Nordisk A/S - Act Now
31 Aug 2025 Announcement Novo Nordisk’s Wegovy® cuts risk of heart attack, stroke or death by 57% compared to tirzepatide in real-world study of people with obesity and cardiovascular diseas
26 Aug 2025 CNBC Eli Lilly’s weight loss pill orforglipron clears its latest trial, paving way for approval
24 Aug 2025 CNBC Eli Lilly's obesity pill remains a viable rival to Novo's oral Wegovy despite data that underwhelmed investors
21 Aug 2025 CNBC FDA approves first-ever glucose monitoring system for weight loss from Signos 
20 Aug 2025 Announcement Novo Nordisk to present Wegovy® and Ozempic® data showing life-saving cardiovascular benefits for people living with obesity and type 2 diabetes at the European Society of Cardiology Congress 2025
19 Aug 2025 CNBC Viking Therapeutics shares fall 40% on disappointing obesity pill trial data
19 Aug 2025 Announcement BioMed X and Novo Nordisk Launch New Collaboration in Oral Peptide Drug Delivery
18 Aug 2025 CNBC Novo Nordisk offers diabetes drug Ozempic for less than half the price for cash-paying U.S. patients
15 Aug 2025 Announcement Wegovy® approved by FDA for the treatment of adults with noncirrhotic MASH with moderate to advanced liver fibrosis
15 Aug 2025 Announcement Novo Nordisk A/S: Wegovy® approved in the US for the treatment of MASH
07 Aug 2025 CNBC Eli Lilly shares drop after obesity pill shows modest late-stage trial results
07 Aug 2025 Announcement Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
06 Aug 2025 Announcement Novo Nordisk's sales increased by 16% in Danish kroner and by 18% at constant exchange rates to DKK 154.9 billion in the first six months of 2025
Show more
TTM Dividend Yield 2.08%
5Y Average Dividend Yield 2.48%
Payout Ratio 47.09%
Expected Next Dividend Payment Apr 2026
Ex Date Announcement Date Payment Date Details
31 Mar 2025 05 Feb 2025 08 Apr 2025 1.099206 Cash
16 Aug 2024 06 Aug 2024 26 Aug 2024 0.5126402 Cash
22 Mar 2024 31 Jan 2024 02 Apr 2024 0.92985 Cash
18 Aug 2023 10 Aug 2023 29 Aug 2023 0.8835613 Cash
24 Mar 2023 02 Feb 2023 04 Apr 2023 1.1887415 Cash
12 Aug 2022 04 Aug 2022 23 Aug 2022 0.5835507 Cash
25 Mar 2022 02 Mar 2022 05 Apr 2022 1.022423 Cash
16 Aug 2021 - 25 Aug 2021 0.5502889 Cash
26 Mar 2021 - 07 Apr 2021 0.922122 Cash
14 Aug 2020 06 Aug 2020 25 Aug 2020 0.5177774 Cash
27 Mar 2020 06 Feb 2020 07 Apr 2020 0.7826048 Cash
16 Aug 2019 10 Aug 2019 27 Aug 2019 0.449438 Cash
22 Mar 2019 05 Feb 2019 02 Apr 2019 0.777006 Cash
17 Aug 2018 09 Aug 2018 28 Aug 2018 0.462327 Cash
23 Mar 2018 24 Mar 2018 03 Apr 2018 0.805982 Cash
17 Aug 2017 - 29 Aug 2017 0.33589 Cash
23 Mar 2017 - 04 Apr 2017 0.479369 Cash
11 Aug 2016 - 23 Aug 2016 0.331026 Cash
18 Mar 2016 - 30 Mar 2016 0.69943 Cash
19 Mar 2015 - 31 Mar 2015 0.532885 Cash
21 Mar 2014 - 02 Apr 2014 0.606122 Cash
21 Mar 2013 - 02 Apr 2013 2.264307 Cash
22 Mar 2012 - 03 Apr 2012 1.831902 Cash
24 Mar 2011 - 05 Apr 2011 1.357901 Cash
25 Mar 2010 - 07 Apr 2010 0.978615 Cash
19 Mar 2009 - 31 Mar 2009 0.781532 Cash
13 Mar 2008 - 25 Mar 2008 0.678462 Cash
08 Mar 2007 - 20 Mar 2007 0.891779 Cash
09 Mar 2006 - 21 Mar 2006 0.691753 Cash
10 Mar 2005 - 22 Mar 2005 0.61725 Cash
17 Mar 2004 - 29 Mar 2004 0.52096 Cash
26 Mar 2003 - 07 Apr 2003 0.37647 Cash
13 Mar 2002 - 25 Mar 2002 0.2848 Cash
21 Mar 2001 - 02 Apr 2001 0.5681 Cash
24 Mar 2000 - 06 Apr 2000 0.4672 Cash
25 Mar 1999 - 06 Apr 1999 0.4182 Cash
27 Mar 1998 - 08 Apr 1998 0.3051 Cash
25 Apr 1997 - 07 May 1997 0.239 Cash
01 May 1996 - 14 May 1996 0.1806 Cash
Show more

Annual Dividend Yield

Year Annual Dividend ($) Frequency/Year Yield %
2025 1.10 1 2.08
2024 1.44 2 1.68
2023 2.07 2 2.00
2022 1.61 2 2.37
2021 1.47 2 2.63
2020 1.30 2 3.72
2019 1.23 2 4.24
2018 1.27 2 5.51
2017 0.815 2 3.04
2016 1.03 2 5.75
2015 0.533 1 1.84
2014 0.606 1 2.86
2013 2.26 1 12.26
2012 1.83 1 11.22
2011 1.36 1 11.78
2010 0.979 1 8.69
2009 0.782 1 12.24
2008 0.678 1 13.20
2007 0.892 1 13.75
2006 0.692 1 16.54
2005 0.617 1 21.94
2004 0.521 1 19.20
2003 0.376 1 18.38
2002 0.285 1 19.71
2001 0.568 1 28.33
2000 0.467 1 26.40
1999 0.418 1 32.36
1998 0.305 1 22.94
1997 0.239 1 16.57
1996 0.181 1 19.32
Show more

The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.

Portfolio

AI Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2025 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria